Cardio Diagnostics Holdings, Inc.

AI-generated fair value estimate for this company.

Method: Net tangible asset value plus pipeline optionality: $7.43M stockholders' equity as of June 30, 2026 (consisting almost entirely of $5.59M cash against only $0.50M total liabilities) plus an estimated $3.00M risk-adjusted option value for the recently CMS-approved Medicare gapfill reimbursement ($854 per test) on the Epi+Gen CHD and PrecisionCHD epigenetic cardiovascular tests; 2,959,469 shares outstanding.

Reasoning: Cardio Diagnostics has negligible trailing revenue (about $15K) so a cash-flow DCF would be pure speculation; with almost no debt and a clean balance sheet, net tangible asset value is the most defensible floor, augmented by a modest, explicitly risk-adjusted allowance for the commercial ramp now that CMS reimbursement is secured for its two flagship tests.